Zotatifin for Solid Tumors
(Zotatifin Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called Zotatifin for patients with advanced cancers that haven't improved with standard treatments. The drug works by stopping cancer cells from making essential proteins, which may slow or stop the cancer.
Do I have to stop taking my current medications for the Zotatifin trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What makes the drug Zotatifin unique for treating solid tumors?
Who Is on the Research Team?
Douglas Warner, MD
Principal Investigator
EFFECTOR Therapeutics, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with certain advanced solid tumors who've had previous treatments like CDK4/6 inhibitors and are now facing cancer that's resistant or intolerant to standard therapies. They should have tried at least one, but no more than five lines of therapy for metastatic disease, and specific criteria apply based on the type of tumor (ER+, HER2-, KRAS mutation, etc.).Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive eFT226 in dose-escalation cohorts to determine the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD)
Cohort Expansion
Further exploration of safety, pharmacology, and clinical activity of eFT226 monotherapy and in combination with other therapies
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- eFT226
Find a Clinic Near You
Who Is Running the Clinical Trial?
Effector Therapeutics
Lead Sponsor